Skip to Search Skip to Global Navigation Skip to Local Navigation Skip to Content
Show/Hide University Links
Faculty

Dr. George Perry

Dr. George Perry

Professor and Dean of College of Sciences

210-458-4450

 

Research Profile

Wikipedia

RTRN Researchers

 

Research Interests

Our studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease. We have shown that oxidative damage is the initial cytopathology in Alzheimer disease. We are working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals. Our current studies focus on (i) the mechanism for RNA-based redox metal binding; (ii) the consequences of RNA oxidation on protein synthesis rate and fidelity; (iii) the role of redox active metals in mediating prooxidant and antioxidant properties; (iv) the signal transduction pathways altered in Alzheimer disease that allow neurons to evade apoptosis; and (v) mechanism of phosphorylation control of oxidative damage to neurofilament proteins

Recent Publications

Perry EA, Castellani RJ, Moreira PI, Nunomura A, Liu Q, Harris PL, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Neurofilaments are the major neuronal target of hydroxynonenal mediated protein crosslinks. Free Radic Res 47:507-510, 2013.

Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Chribi O, Squitti R, Perry G.  Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 59:100-110, 2013.

Paley EL, Perry G. Sokolova O.  Tryptamine induces axonopathy and mitochondriopathy mimicking neurodegenerative diseases via tryptophanyl-tRNA deficiency.  Curr Alzheimer Res 10:987-1004, 2013.

Fujioka H, Phelix CR, Friedland R, Zhu X, Perry EA, Castellani RJ, Perry G.  Apolipoprotein E4 prevents growth of Plasmodium falciparum at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer disease.  J Health Care for the Poor and Underserved 24:70-78, 2013.

Williams WM, Richardson S, Siedlak SL, Castellani RJ, Perry G, Smith MA, Zhu X.  Antimicrobial Peptide beta-defensin-1 expression is upregulated in Alzheimer’s brain. J Neuroinflammation 10, http://www.jneuroinflammation.com/content/10/1/127, 2013.

Castellani RJ, Nugent SL, Morrison AL, Zhu X, Lee H-g, Harris PLR, Bajić V, Sharma HS, Chen SG, Oettgen P, Perry G, Smith MA.  CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson’s disease.  J Neural Transm 118:23-26, 2011.

Phelix CF, LeBaron RG, Roberson DJ, Villanueva RE, Villareal G, Rahimi OB, Siedlak S, Zhu X, Perry G.  Transcription-to-metabalome biosimulation reveals human hippocampal hypometabolism with age and Alzheimer’s disease.  Intern J Knowledge Discovery Bioinformatics 2:1-18, 2011.

Valdez CM, Phelix CF, Smith MA, Perry G, Santamaria F.  Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Molecular Biosystems 7:1891-1901, 2011.

Stone JG, Siedlak SL, Tabaton M, , Hirano A, Castellani RJ, Santocanale C, Perry G, Smith MA, Zhu X, Lee H-g.  The cell cycle regulator, phosphorylated retinoblastoma protein, is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol 70:578-587, 2011.

Wang X, Su B, Liu W, He X, Gao Y, Castellani RJ, Perry G, Smith MA, Zhu X.  DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinum toxicity in neurons:  implications for Parkinson’s disease. Aging Cell 10:807-823, 2011.

Wise-Scira O, Xu L, Kitahara T, Perry G, Coskuner O.  Amyloid-β peptide structure in aqueous solution varies with fragment size.  J Chem Phys 135:205101-1–205101-13, 2011 (Virtual J Biol Phys Res, 22(11), 2011).

Colom LV, Castaneda MT, Hernandez S, Perry G, Jaime S, Touham A.  Intrahippocampal amyloid-β (1-40) injections injure medial septal neurons.  Curr Alzheimer Res 8:832-840, 2011.

Castellani RJ, Gupta Y, Sheng B, Siedlak SL, Harris PLR, Coller JM, Perry G, Lee H-g,  Tabaton M, Smith MA, Wang X, Zhu X.  A novel origin for granulovacuolar degeneration in aging and Alzheimer’s disease:  parallels to stress granules.  Lab Invest 91:1777-1786, 2011.

Zhu X, Castellani RJ, Moreira PI, Aliev G, Shenk JC, Siedlak SL, Harris PLR, Fujioka H, Sayre LM, Szweda PA, Szweda LI, Smith MA, Perry G. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover.  Free Rad Biol Med 52:699-704, 2012.

Nunomura A, Tamaoki T, Motohashi N, Nakamura M, McKeel Jr. DW, Tabaton M, Lee H-g, Smith MA, Perry G, Zhu X.  The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons.  J Neuropathol Exp Neurol 71:233-241, 2012.

Calderón-Garcidueñas L, Kavanaugh M, Block M, D’Angiulli A, Delgado-Chάvez R, Torres-Jardón R, González-Maciel A, Reynoso-Robles R, Perry G, Osnaya N, Villarreal-Calderon R, Guo R, Hua Z, Zhu H, Perry G, Diaz P.  Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimer’s Dis 28:93-107, 2012.

Gugliemotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M.  AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation Neurobiol Aging 33:196e.13-196e.27, 2012.

Sheng B, Wang X, Su B, Lee H-G, Casadesus G, Perry G, Zhu X.  Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease.  J Neurochem 120:419-429, 2012.

Kudo W, Lee H-P, Zou W-Q, Perry G, Zhu X, Smith MA, Petersen RB, Lee H-G.  Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Human Mol Genetics 21:1138-1144, 2012.

Wang X, Yan MH,Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X.  LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Mol Genetics 21:1931-1944, 2012.

Greco SJ, Hamzelou A, Johnston JM, Richardson S, Smith MA, Perry G, Ashford JW, Tezapsidis N.  Isotyping the human TOMM40 variable-length polymorphism by gene amplification and restriction digest Curr Alzheimer Res 9:1168-1173, 2012.

Wise-Scira O, Xu L, Perry G, Coskuner O.  Scructures and free energy landscapes of aqueous Zinc (II)-bound Amyloid-β (1-40) and Zinc (II)-bound Amyloid β (1-42) with dynamics.  J Biol Inorg Chem 17:927-938, 2012.

Piccini A, Borghi R, Guglielmotto M, Tamagno E, Cirmena G, Garuti A, Pollero V, Cammarata S, Fornaro M, Messa M, Colombo L, Salmona M, Perry G, Tabaton M.  β-amyloid 1-42 induces physiological transcriptional regulation of BACE1.  J Neurochem 122:1023-1031, 2012.

Coskuner O, Wise Scira O, Perry G.  The structures of the E22∆ mutant-type Amyloid-β alloforms and the impact of E22∆ mutation on the structures of the wild-type Amyloid-β alloforms..  ACS Chem Neurosci 4:310-320, 2013.

Greco SJ, Perry G, Ashford JW, Hamzelou A, Johnston JM, Tezapsidis N.  Leptin rescues neurons from alzheimer’s disease-related pathways triggered by lipid burden. Adv Alzheimer’s Dis 2:31-39, 2013.

Correia SC, Santos RX, Santos MS, Casadesus G, LaManna JC, Perry G, Smith MA, Moreira PI.  Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease Current Alzheimer Res 10:406-419, 2013.

Durán-González J, Michi ED, Elorza B, Perez-Córdova MG, Pacheco-Otalora LF, Touhami A, Paulson P, Perry G, Murray IV, Colom LV. Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system, Neurobiol Aging 34:2071-2076, 2013.